Angio8, a Shenzhen-based developer of vascular interventional surgical robots, has reportedly raised tens of millions of renminbi through a Series A financing round. The investment was led by Oriental Fortune Capital, with participation from Kangyu Capital, marking a significant milestone in the company’s growth and development trajectory.
Commitment to First-In-Class Vascular Interventional Surgery Solutions
Founded in 2021, Angio8 is dedicated to the development of a first-in-class vascular interventional surgery robot platform, aiming to provide intelligent surgery solutions. This commitment to innovation positions Angio8 at the forefront of medical robotics, focusing on enhancing surgical outcomes through advanced robotic technology.
Funding to Fuel Product Development and Clinical Advancement
The capital raised will be instrumental in ramping up product research and development efforts. It will also support the advancement of Angio8’s robotic solutions into clinical settings, where they can be rigorously tested and refined for broader application in the healthcare sector.-Fineline Info & Tech
